AAAAAA

   
Results: 1-14 |
Results: 14
Exclusion of mitral valvuloplasty from predictors of mortality for patients undergoing cardiac valve replacements in New York State - Reply
Authors: Gold, JP Hannan, EL Racz, MJ Jones, RH Ryan, TJ Hafner, JP Isom, OW
Citation: Jp. Gold et al., Exclusion of mitral valvuloplasty from predictors of mortality for patients undergoing cardiac valve replacements in New York State - Reply, ANN THORAC, 72(2), 2001, pp. 663-663
Preoperative predictors of late postoperative outcome among patients with nonischemic mitral regurgitation with 'high risk' descriptors and comparison with unoperated patients
Authors: Wencker, D Borer, JS Hochreiter, C Devereux, RB Roman, MJ Kligfield, P Supino, P Krieger, K Isom, OW
Citation: D. Wencker et al., Preoperative predictors of late postoperative outcome among patients with nonischemic mitral regurgitation with 'high risk' descriptors and comparison with unoperated patients, CARDIOLOGY, 93(1-2), 2000, pp. 37-42
Predictors of mortality for patients undergoing cardiac valve replacementsin New York State
Authors: Hannan, EL Racz, MJ Jones, RH Gold, JP Ryan, TJ Hafner, JP Isom, OW
Citation: El. Hannan et al., Predictors of mortality for patients undergoing cardiac valve replacementsin New York State, ANN THORAC, 70(4), 2000, pp. 1212-1218
Transmyocardial laser revascularization with excimer laser: Clinical results at 1 year
Authors: Lee, LY O'Hara, MF Finnin, EB Hachamovitch, R Szulc, M Kligfield, PD Okin, PM Isom, OW Rosengart, TK
Citation: Ly. Lee et al., Transmyocardial laser revascularization with excimer laser: Clinical results at 1 year, ANN THORAC, 70(2), 2000, pp. 498-503
Repair of traumatic aortic valve disruption and descending aortic transection
Authors: Girardi, L Isom, OW
Citation: L. Girardi et Ow. Isom, Repair of traumatic aortic valve disruption and descending aortic transection, ANN THORAC, 69(4), 2000, pp. 1251-1253
Focal angiogen therapy using intramyocardial delivery of an adenovirus vector coding for vascular endothelial growth factor 121
Authors: Lee, LY Patel, SR Hackett, NR Mack, CA Polce, DR El-Sawy, T Hachamovitch, R Zanzonico, P Sanborn, TA Parikh, M Isom, OW Crystal, RG Rosengart, TK
Citation: Ly. Lee et al., Focal angiogen therapy using intramyocardial delivery of an adenovirus vector coding for vascular endothelial growth factor 121, ANN THORAC, 69(1), 2000, pp. 14-23
Pheochromocytoma of the heart
Authors: Pickering, TG Isom, OW Bergman, GW Barbieri, JM
Citation: Tg. Pickering et al., Pheochromocytoma of the heart, AM J CARD, 86(11), 2000, pp. 1288
Severe mitral regurgitation due to mitral valve prolapse: Risk factors fordevelopment, progression, and need for mitral valve surgery
Authors: Singh, RG Cappucci, R Kramer-Fox, R Roman, MJ Kligfield, P Borer, JS Hochreiter, G Isom, OW Devereux, RB
Citation: Rg. Singh et al., Severe mitral regurgitation due to mitral valve prolapse: Risk factors fordevelopment, progression, and need for mitral valve surgery, AM J CARD, 85(2), 2000, pp. 193-198
Predictors and outcomes of cardiac complications following elective coronary bypass grafting
Authors: Charlson, M Krieger, KH Peterson, JC Hayes, J Isom, OW
Citation: M. Charlson et al., Predictors and outcomes of cardiac complications following elective coronary bypass grafting, P ASS AM PH, 111(6), 1999, pp. 622-632
Safety of direct myocardial administration of an adenovirus vector encoding vascular endothelial growth factor 121
Authors: Patel, SR Lee, LY Mack, CA Polce, DR El-Sawy, T Hackett, NR Ilercil, A Jones, EC Hahn, RT Isom, OW Rosengart, TK Crystal, RG
Citation: Sr. Patel et al., Safety of direct myocardial administration of an adenovirus vector encoding vascular endothelial growth factor 121, HUM GENE TH, 10(8), 1999, pp. 1331-1348
A comparison of three-year survival after coronary artery bypass graft surgery and percutaneous transluminal coronary angioplasty
Authors: Hannan, EL Racz, MJ McCallister, BD Ryan, TJ Arani, DT Isom, OW Jones, RH
Citation: El. Hannan et al., A comparison of three-year survival after coronary artery bypass graft surgery and percutaneous transluminal coronary angioplasty, J AM COL C, 33(1), 1999, pp. 63-72
Angiogenesis gene therapy - Phase I assessment of direct intramyocardial administration of an adenovirus vector expressing VEGF121 cDNA to individuals with clinically significant severe coronary artery disease
Authors: Rosengart, TK Lee, LY Patel, SR Sanborn, TA Parikh, M Bergman, GW Hachamovitch, R Szulc, M Kligfield, PD Okin, PM Hahn, RT Devereux, RB Post, MR Hackett, NR Foster, T Grasso, TM Lesser, ML Isom, OW Crystal, RG
Citation: Tk. Rosengart et al., Angiogenesis gene therapy - Phase I assessment of direct intramyocardial administration of an adenovirus vector expressing VEGF121 cDNA to individuals with clinically significant severe coronary artery disease, CIRCULATION, 100(5), 1999, pp. 468-474
Six-month assessment of a phase I trial of angiogenic gene therapy for thetreatment of coronary artery disease using direct intramyocardial administration of an adenovirus vector expressing the VEGF121 cDNA
Authors: Rosengart, TK Lee, LY Patel, SR Kligfield, PD Okin, PM Hackett, NR Isom, OW Crystal, RG
Citation: Tk. Rosengart et al., Six-month assessment of a phase I trial of angiogenic gene therapy for thetreatment of coronary artery disease using direct intramyocardial administration of an adenovirus vector expressing the VEGF121 cDNA, ANN SURG, 230(4), 1999, pp. 466-470
Outcome analysis of 245 CarboMedics and St. Jude valves implanted at the same institution
Authors: Rosengart, TK O'Hara, M Lang, SJ Ko, W Altorki, N Krieger, KH Isom, OW
Citation: Tk. Rosengart et al., Outcome analysis of 245 CarboMedics and St. Jude valves implanted at the same institution, ANN THORAC, 66(5), 1998, pp. 1684-1691
Risultati: 1-14 |